An additional 18% of physicians (24/197 endocrinologists and 48/203 PCPs) indicated that while they would not prescribe SGLT2 inhibitors in type 2 diabetes mellitus patients at low risk of diabetic kidney disease, they would order SGLT2 inhibitors for their patients at an increased risk of diabetic kidney disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.